TempraMed Expands South Korean Partnership as Injectable Drug Demand Surges

TempraMed Technologies Ltd. ( (TSE:VIVI) ) has shared an update.

TempraMed Technologies has expanded its distribution partnership with South Korea–based Mavericks Co. Ltd. and secured a new commercial order, deepening its penetration into one of Asia’s fastest-growing markets for injectable therapies. The move follows the granting of a South Korean patent for TempraMed’s thermal-insulation technology and the launch of its digitally connected VIVI Cap Smart device, positioning the company to better serve rising local demand for temperature-sensitive medications such as insulin, GLP-1 receptor agonists, biologics and emergency injectables. By leveraging Mavens’ established relationships across pharmacies, hospitals and clinics, TempraMed aims to accelerate its reach among patients with chronic conditions, while the deal also builds on recent distribution agreements in Turkey, Israel and Europe, underscoring a broader global expansion strategy and strengthening its presence in key healthcare and retail ecosystems.

More about TempraMed Technologies Ltd.

TempraMed Technologies Ltd. is a medical-technology company specializing in innovative, temperature-controlled medication storage solutions. The company develops patented, FDA-registered, space-grade thermal insulation devices, such as VIVI Cap and VIVI Epi, which work without batteries or external power to protect temperature-sensitive medications. Headquartered in Israel with operations in North America, Europe, and Asia, TempraMed targets patients and healthcare providers who rely on injectable and other temperature-sensitive therapies, and is expanding into smart, digitally connected platforms like its new VIVI Cap Smart device.

Average Trading Volume: 32,728

See more insights into VIVI stock on TipRanks’ Stock Analysis page.